Histotripsy of Liver Tumors: Patient Selection, Ethical Discussions, and How We Do It
Cancers · 25.03.2025 · 17 (7) · 1100
DOI: 10.3390/cancers17071100 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.03.2025. Verfasst von Melis Uysal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Department of General Surgery, Digestive Disease & Surgery Institute, Cleveland, OH 44120, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Liver malignancies, both primary and metastatic tumors, are a major cause of cancer-related mortality. Colorectal cancer alone results in liver metastases in nearly 50% of patients, with approximately 85% presenting with unresectable disease. Similarly, hepatocellular carcinoma and intrahepatic cholangiocarcinoma frequently present at advanced stages, limiting curative options. Systemic therapies provide modest survival benefits, underscoring the need for alternative treatments. Locoregional approaches, such as thermal ablation and chemoembolization, while effective, have notable limitations, including invasiveness, peri-procedural risks, and the requirement to interrupt systemic treatments. Histotripsy is a novel, non-invasive method that uses focused ultrasound-induced cavitation to enable precise tumor ablation without heat or radiation. Our institution utilizes a multidisciplinary tumor board approach to evaluate patients for histotripsy, particularly in cases involving unresectable disease, complex surgical candidacy, palliative intent related to disease control and symptom management, or as bridging therapy for transplantation. Early results, including preclinical data and the THERESA and #HOPE4LIVER trials, highlight its efficacy in treating liver tumors with minimal complications. This review outlines institutional protocols for histotripsy, covering pre- and post-procedural management, along with ethical considerations of current treatment paradigms. As a patient-centered approach, histotripsy offers a novel treatment option with a favorable safety profile and compatibility with systemic therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cleveland Clinic, Department of General Surgery, Digestive Disease & Surgery Institute, Cleveland, OH 44120, USA.
ORCID-Profile: Melis Uysal, Chase J Wehrle, JaeKeun Kim
Zitieren
APA
Uysal, M., Wehrle, C. J., Satish, S., Knott, E., Hong, H., Allkushi, E., Schlegel, A., Berber, E., Aucejo, F., Kim, J., & Kwon, D. C. H. (2025). Histotripsy of Liver Tumors: Patient Selection, Ethical Discussions, and How We Do It. Cancers, 17(7), 1100. https://doi.org/10.3390/cancers17071100
Vancouver
Uysal M, Wehrle CJ, Satish S, Knott E, Hong H, Allkushi E, et al. Histotripsy of Liver Tumors: Patient Selection, Ethical Discussions, and How We Do It. Cancers. 2025;17(7):1100. doi:10.3390/cancers17071100
BibTeX
@article{Uysal2025,
author = {Uysal, Melis and Wehrle, Chase J and Satish, Sangeeta and Knott, Emily and Hong, Hanna and Allkushi, Erlind and Schlegel, Andrea and Berber, Eren and Aucejo, Federico and Kim, JaeKeun and Kwon, David C H},
title = {Histotripsy of Liver Tumors: Patient Selection, Ethical Discussions, and How We Do It},
journal = {Cancers},
year = {2025},
volume = {17},
number = {7},
pages = {1100},
doi = {10.3390/cancers17071100}
}
EUVIMED